Locations
Indianapolis, IN, USA
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Other
founded in
2005
Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing APX3330, an orally-administered drug targeting the APE1/Ref-1 protein, which plays a critical role in various cancers and inflammatory diseases. The company aims to address high unmet medical needs in conditions such as diabetic macular edema and chemotherapy-induced peripheral neuropathy. With a strong scientific foundation and a robust pipeline of second-generation compounds, Apexian is positioned to make significant advancements in cancer treatment and related disorders.
Is this your company?
Something looks off?